Drug Design, Development and Therapy

Dovepress
open access to scientific and medical research

Open Access Full Text Article

CORRIGENDUM

# Sulfasalazine Inhibits Inflammation and Fibrogenesis in Pancreas via NF-κB Signaling Pathway in Rats with Oxidative Stress-Induced Pancreatic Injury [Corrigendum]

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/
For personal use only.

Wang Y, Tian F, Yan M, et al. *Drug Des Dev Ther*. 2016;10:1743–1751.

The authors have advised Figure 1A on page 1746 is incorrect. The authors inadvertently chose b and c from the same group of candidate representative images during figure assembly. The correct Figure 1 is shown below.

The authors apologize for this error and advise it does not affect the results of the paper.




**Figure 1** Pancreatic histological alterations (**A**) and histological scores (**B**).
**Notes:** (**A**, H&E staining, original magnification 200×) Representative histological changes in pancreas in normal group (a), group DS1 (b), DS2 (c), DS3 (d), and DDC (e). Quantitative analysis (**B**) demonstrates different pancreatic histological alterations in rats with different sulfasalazine (SF) treatments in different groups. Group N, normal control group, rats were treated with dilated water only; DS1, rats received SF (10 mg/kg) 2 hours before DDC treatment; group DS2, rats were treated with DDC and then SF (100 mg/kg, twice a week); group DS3, rats were treated with DDC, then SF (100 mg/kg, thrice a week); and group DDC, rats were treated with DDC only.
**Abbreviations:** H&E, hematoxylin and eosin; DDC, diethyldithiocarbamate.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

**Submit your manuscript here:** https://www.dovepress.com/drug-design-development-and-therapy-journal

https://doi.org/10.2147/DDDT.S324356

Received: 11 June 2021
Accepted: 11 June 2021
Published: 16 June 2021



© 2021 Wang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).